THIS SHARE WILL BE WORTH 3.00 IN 2009

Iam glad that Iam not the only person who has overspent on s.e.o so have no money left to buy these at this price /Ihope we have done the right thing///

Protherics to resubmit its Voraxaze(TM) BLA following FDA data request.
Still looking good for Voraxaze, but any delay is bad news even if it appears to be only 6 months (a small time in the drug world).
This looks worse than it is probably due to being on the back of the previous RNS.
Shares look a good buy at this price, as long as a term of at least 1 to 2 years is being looked at.

There will be further downtrend in the short term...IMO to 60p

Hlyeo,

Could be right but I think the drop has been overdone, they usually are.
I expect it to end the week still down but with some recovery.

The drop has been well overdone. We're in the same place we were this time yeasterday, just 6 months further away. Not a justification for such a large drop. This will definately bounce back.

but delays in product coming onto the market means loss of income. I think it will go lower.

Agree it means income coming in later (about 6 months) but if you look at the whole picture, did this delay warrant a drop of that percentage.
They have other products already producing income. Their financial situation is also good. They have a good R+D set up, excellent management and a health product line.

The Independent has Protherics as a buy

"Investors should use the recent weakness in Protherics stock, due to delays two drugs under development, as a buying opportunity.The company is among the most well-financed in the biotechnology sector. While via CytoFab, it, and partner AstraZeneca, pretty much have the 4bn sepsis market to themselves."

Hi Kim,

Nice little write up. Says it all really.
The way this day has started looks like punters are doing just that (a buying opportunity.).

Hi GM, I'm hoping this won't be as stressful as SEO!!!
kim

Kim,

I would think that would be impossible, ( I hope).

Well there was a bounce today as I predicted. More to come tomorrow?

http://www.cnw.ca/fr/releases/archive/November2006/16/c5550.html

Scrip Awards
LONDON, Nov. 16 /CNW/ - "It is only the second year, but the world now
has Scrip Awards written on its heart 600-plus international guests attended the second Scrip Awards ceremony, held at the Grosvenor House Hotel in London.


Well we all thought it was a good deal between Protherics and AstraZeneca, now it looks better than ever. This lot presumably know what they are on about.
Anything such as this bring PTI more into the public but mainly the private eye view of the pharmaceutical industry.
All the big names were obviously there. It must me like the Oscar Awards for the drug industry.
The whole article is not very interesting but if you want a look, see link.

Licensing Deal of the Year
Sponsored by Imperial Innovations
Winner - Protherics and AstraZeneca
For those who remember the deal was announced on 8th December 2005.

A ringing endorsement greekman. Let's hope this helps to settle investors nerves that have been jangling a little over the past fortnight.

Hi Q,

I think it will as it already appears to have calmed down somewhat.
No matter what the share there are always those interested in a quick buck (me included), but Protherics is one to put away for 1 to 3 years.
Obviously in the drug business, as we know no matter how well trials are going, it can go wrong at the last hurdle.

Indeed. But like you I'm squirreling away for that sunny day :-)

RNS with excellent news.
It looks like DigiFabTM is a great improvement on Roche's Digitalis Antidote(R).
Also with a nice close working relationship with Roche, it makes an even more viable future for PTI. Roche AND AstraZeneca.
Protherics is now really playing with the big boys.

Protherics PLC
27 November 2006

Protherics PLC

Protherics' DigiFabTM to replace Digitalis Antidot(R) in Europe


London, UK; Brentwood, TN, US: 27 November 2006 - Protherics PLC ('Protherics'
or the 'Company'), the international biopharmaceutical company focused on
critical care and cancer, today announces the transfer of market rights for
Digitalis Antidot(R) from Roche to Protherics, with the intention of replacing
Roche's Digitalis Antidot(R) in the market with Protherics' own digitalis
antidote DigiFabTM from early 2007.

Roche's Digitalis Antidot(R) is currently approved in France, Germany and
Switzerland. Protherics has acquired the market rights for Digitalis Antidot(R)
for a small undisclosed cash consideration, and is working with Roche to
facilitate the smooth transition in the market from Digitalis Antidot(R) to
DigiFabTM.

DigiFabTM is an ovine derived Fab preparation for the treatment of digoxin
toxicity which can have severe effects on the heart and central nervous system,
sometimes leading to death. It is currently licensed by the US Food and Drug
Administration for the treatment of patients with life-threatening or
potentially life-threatening digoxin toxicity or overdose. Marketing
authorisation will be sought in major European countries, including France,
Germany, Spain and Italy, following grant of approval in the UK, expected early
in 2007. Protherics will continue to make DigiFabTM available on a named
patient basis.

DigiFabTM will be marketed in most mainland European countries by Protherics'
licensee, Beacon Pharmaceuticals. Protherics will be directly responsible for
marketing and sales in Germany, one of the major European markets, as well as in
the Nordic countries.

Andrew Heath, Chief Executive of Protherics said:

'Protherics' goal is to become the global market leader in the anti-digoxin
antibody market. We are pleased to be co-operating with Roche in arranging for
a smooth market transition from Digitalis Antidot(R) to DigiFabTM in order to
ensure continued patient care for this potentially life-threatening condition.'

Eugene Tierney, Business Director at Roche said:

'Roche has been looking for a company that can take over its digitalis antidote
business, to ensure that it remains available for patients to treat
intoxication. We are pleased that Protherics, a company experienced in that
business, will be supplying the market.'





For further information please contact:


Protherics
Andrew Heath, CEO +44 (0) 20 7246 9950
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Saul Komisar, President Protherics Inc +1 615 327 1027

Financial Dynamics - press enquiries
London: Ben Atwell, David Yates, Anna Keeble +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt +1 212 850 5600

I know it's still early, but I would have expected the sp to have moved up at least 5p on the news, especially after its dip that was overdone a couple of weeks ago.
I am sure the institutions will be buying this week.
Unfortunately, no spare cash to top up.
I wonder if Astrazeneca and Roche will view Protherics as an even more R+D productive target.
The competition in the pharmaceutical world is strong. If one company gets any inkling of the other sniffing around, you never know.
I am a strong believer in PTI as a future strong player in its field.
I hope that they stay independent.
But due to consolidation in the drugs market, you never know.